I'm unable to access the specific content from the Xeris Pharmaceuticals website as the page is restricted. However, I can provide a general overview of the types of technologies that companies like Xeris Pharmaceuticals typically focus on. 

Xeris Pharmaceuticals is known for its innovative drug delivery technologies, particularly in the development of formulations that enhance the bioavailability and stability of therapeutic agents. Their proprietary platforms often include advanced methods for creating injectable formulations that can improve patient compliance and treatment outcomes. Additionally, the company may utilize technologies that allow for the sustained release of medications, which can reduce the frequency of dosing and improve overall therapeutic efficacy. 

If you have specific information or text from the website that you can share, I would be happy to help summarize that content accurately.

United States

Xeris is a specialty pharmaceutical company leveraging novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables.

Endocrine System Diseases

Genetic Diseases

Metabolic Diseases

Musculoskeletal Diseases

Xeris Pharmaceuticals 

Cushing’s syndrome

Rare diseases

RECORLEV (levoketoconazole), or COR-003, is an investigational cortisol synthesis inhibitor. It has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing's syndrome.
RECORLEV (levoketoconazole) is the pure 2S,4R enantiomer of ketoconazole, a steroidogenesis inhibitor used to treat endogenous Cushing’s syndrome. Ketoconazole is recommended for use in treating Cushing's syndrome, but is not approved for that use in the US. We believe that RECORLEV (levoketoconazole) may have favorable efficacy, safety, and tolerability for patients with <a href="https://www.strongbridgebio.com/therapeutic-focus/endogenous-cushings-syndrome/">endogenous Cushing’s syndrome</a> (<a href="https://www.strongbridgebio.com/products/recorlev/">Learn more HERE</a>).&nbsp;

Recorlev® (levoketoconazole)

Diabetes

Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.

Gvoke®

Dichlorphenamide is a carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011366s033lbl.pdf">Learn more HERE</a>).

Keveyis® (dichlorphenamide)

Adult hypoparathyroidism

Therapeutically, levothyroxine is administered when the body is deficient in the endogenous hormone. Administration of levothyroxine is thus indicated for acquired thyroid disease (primary hypothyroidism), in cases of decreased secretion of TSH from the anterior pituitary gland (secondary hypothyroidism), and in cases of decreased secretion of TRH from the hypothalamus (tertiary hypothyroidism) and for congenital hypothyroidism. In most patients, hypothyroidism is a permanent condition requiring lifelong treatment. The goal of therapy is restoration of the euthyroid state, which can reverse the clinical manifestations of hypothyroidism and significantly improve quality of life.

XeriSol® (Levothyroxine) (XP-8121)

Hypoglycemia

Glucagon is a metabolic hormone secreted by the pancreas that raises blood glucose levels by causing the liver to rapidly convert glycogen (the stored form of glucose) into glucose, which is then released into the bloodstream. Glucagon and insulin are two critical hormones in a glycemic control system that keep blood glucose at the right level in healthy individuals. In people with diabetes who are dependent on insulin, this control system is disrupted, and insulin must be injected to avoid high levels of blood glucose (hyperglycemia). The opposite effect, or low blood glucose (hypoglycemia), is also prevalent in this population due to dysregulated glucagon secretion. Severe hypoglycemia is a serious condition and can lead to seizures, coma, potential brain injury and, if untreated, death.
 
Glucagon is the standard of care for treating severe hypoglycemia. According to the American Diabetes Association, glucagon should be prescribed for all individuals at increased risk of clinically significant hypoglycemia, defined as blood glucose &lt;54 mg/dL (3.0 mmol/L). Leveraging XeriSol™, one of Xeris’ two proprietary formulation technology platforms, Xeris has the potential to provide the first ready-to-use, room-temperature stable liquid glucagon for use by people with diabetes and other conditions to prevent or manage various forms of hypoglycemia and improve glucose control.

Self-Administered Glucagon / ready-to-use (RTU) glucagon

Type 1 diabetes

Type 2 diabetes

Pramlintide is an analog of amylin, a natural hormone that inhibits glucagon secretion, delays gastric emptying, and is known to help increase satiety. Pramlintide is indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy. It works by slowing the movement of food through the stomach. This prevents blood sugar from rising too high after a meal and may decrease appetite and cause weight loss. Pramlintide use with insulin has been associated with an increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes.

Xeris Pharmaceuticals

Company Details